Welcome to Sana Securities! Login | Subscribe Now.

Alembic Pharmaceuticals Equity Research

HomeCompanyAlembic Pharmaceuticals Equity Research

Date of Research – 12 January, 2016

Price – Rs. 673.85

About the Company

Established in 1907, Alembic Pharmaceuticals Limited (“Alembic” or the “Company“) is one of the leading pharmaceutical company in India. The Company develops, manufactures and markets pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in the segment of anti-infective drugs in India.

The Company’s manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market.

Key Financial Figures

Consolidated (Rs. Cr)
Particulars FY 2013 FY 2014 FY 2015 FY 2016 FY 2017
Total Income from Operations 1,519.34 1,863.21 2,056.12 3,148.71  3,134.61
Expenses 1,267.38 1,505.50 1,653.15 2,142.74   2,519.89 
Earnings Before Other Income, Interest, Tax and Depreciation (Operating Profit) 251.96 357.71 402.97 1,005.97   614.72 
Depreciation 34.97 40.49 44.41 72.21   82.97 
Finance Costs 14.57 9.81 1.78 3.68   5.12 
Other income 3.93 3.19 2.30 5.51   2.47 
PBT 206.35 310.60 359.08 935.59   529.10 
Tax 41.10 75.10 76.35 216.01   122.19 
PAT (before Minority Interest and share of Associates) 165.25 235.50 282.73 719.58   406.91 
Share of profit / (loss) of Associates (0.20) 0.15   3.83 
Profit attributable to Minority Interest (0.09) 
Consolidated Profit / (Loss) for the year 165.25 235.50 282.93 719.43   403.17 

Profitability Analysis

Consolidated (%)
Particulars FY 2013 FY 2014 FY 2015 FY 2016 FY 2017
Operating Profit Margin Ratio 16.58 19.20 19.60 31.95   19.61
Net Profit Margin Ratio 10.88 12.64 13.75 22.85   12.98

Operating profit margin is a measurement of the proportion of a company’s revenue that is left over after paying for production costs such as raw materials, salaries and administrative costs. Net profit margin is arrived at by deducting non operating expenses such as depreciation, finance costs and taxes out of operating profit and shows what is left for the shareholders as a percentage of net sales. Together these ratios help in understanding the cost and profit structure of the firm and analysing business inefficiencies.

Key Balance Sheet Figures

Sources of Funds / Liabilities (Rs. Cr)
Particulars FY 2012 FY 2013 FY 2014 FY 2015 FY 2016 
Share Capital 37.70 37.70 37.70 37.70 37.70 
Reserves & Surplus 351.83 458.54 623.80 837.66 1,547.17 
Foreign Currency Translation Reserve 15.66
Net worth (shareholders funds) 389.53 496.25 661.50 875.36 1,600.54
Long term borrowings 94.86 70.53 52.22 18.80
Current liabilities 534.84 441.63 447.91 684.09 767.43
Other long term liabilities and provisions 23.15 25.52 33.45 31.48 41.28
Deferred Tax Liabilities 9.53 13.90 22.72 31.43 50.13
Total Liabilities 1,051.90 1,047.82 1,217.80 1,641.17 2,459.38

 

Application of Funds / Assets (Rs. Cr)
Particulars FY 2012 FY 2013 FY 2014 FY 2015 FY 2016 
Fixed Assets 326.06 376.48 417.63 630.01 867.30 
Noncurrent Investments 3.30 3.30 3.36 2.26 2.11
Current assets 687.55 632.16 755.17 890.74 1,506.56
Long term advances and other noncurrent assets 34.99 35.88 41.64 118.15 83.40
Total assets 1,051.90 1,047.82 1,217.80 1,641.17 2,459.38

Efficiency Analysis

  (%)
Particulars FY 2012 FY 2013 FY 2014 FY 2015 FY 2016 
ROCE 45.50 44.45 50.12 45.07 62.85 
ROE / RONW 33.41 33.30 35.60 32.32 44.96 

Return on Capital Employed (ROCE) measures a company’s profitability from its overall operations by calculating the return generated on the total capital invested in the business (i.e. equity + debt). Return on Equity (ROE) or Return on Net Worth (RONW) measures the amount of profit which the company generates on money invested by the equity shareholders. In short, ROE draws attention to the return generated by the shareholders on their investment in the business. Together these ratios can be used in comparing the profitability of the company with other companies in the same industry.

Valuation Analysis

Consolidated
Particulars FY 2013 FY 2014 FY 2015 FY 2016 FY 2017
Total Income from Operations (Rs. Cr.) 1,519.34 1,863.21 2,056.12 3,148.71 3,134.61
Growth (%) 3.61 % 22.63 % 10.35 % 53.14 % (0.45 %)
PAT (Rs. Cr.) 165.25 235.50 282.73 719.58 406.91
Growth (%) 26.98 % 42.51 % 20.06 % 154.33 % (43.45 %)
Earnings Per Share – Basic (Rs. ) 8.77 12.49 15.01 38.16 21.39
Earning Per Share – Diluted (Rs. ) 8.77 12.49 15.01 38.16 21.39
Price to Earnings 11.88 22.73 30.05 15.74 27.88

Dividend History

The Company has maintained an average dividend yield of 1.05 % over the last 3 financial years.

Liquidity and Credit Analysis

Current Ratio

Higher current ratio implies healthier short term liquidity comfort level. A current ratio below 1 indicates that the company may not be able to meet its obligations in the short run. However, it is not always a matter of worry if this ratio temporarily falls below 1 as many times companies squeeze out short term cash sources to achieve a capital intensive plan with a longer term outlook. Alembic Pharma’s average current ratio over the last 5 financial years has been 1.53 times which indicates that the Company is comfortably placed to pay for its short term obligations.

Long term Debt to Equity Ratio

Companies operating with high long term debt to equity on their balance sheets are vulnerable to economic cycles. In times of slowdown in economy, companies with high levels of debt find it increasingly difficult to service the interest on their borrowings as profit margins decline. We believe that long term debt to equity ratio higher than 0.6 – 0.8 could affect the business of a company and its results of operations.

Alembic Pharma’s average long term debt to equity ratio over the last 5 financial years has been 0.10 times which indicates that the Company operates with close to zero debt and is placed well to withstand economic slowdowns.

Interest Coverage Ratio

Interest coverage ratio indicates the comfort with which the company may be able to service the interest expense (i.e. finance charges) on its outstanding debt. Higher interest coverage ratio indicates that the company can easily meet the interest expense pertaining to its debt obligations. In our view, interest coverage ratio of below 1.5 should raise doubts about the company’s ability to meet the expenses on its borrowings. Interest coverage ratio below 1 indicates that the company is just not generating enough to service its debt obligations.

Alembic Pharma’s average interest coverage ratio over the last 5 financial years has been 112.38 times which indicates that the Company can meet its debt obligations without any difficulty.

Ownership pattern

In its latest stock exchange filing dated 31 March 2017, Alembic Pharma reported a promoter holding of 72.68 %. Large promoter holding indicates conviction and sincerity of the promoters. We believe that a greater than 35 % promoter holding offers safety to the retail investors.

At the same time, institutional holding in the Company stood at 12.60 % (FII+DII). Large institutional holding indicates the confidence of seasoned investors. At the same time, it can also lead to high volatility in the stock price as institutions buy and sell larger stakes than retail participants.

About the Author

Rajat Sharma pictureRajat Sharma is a well known stock market analyst and commentator. He has covered Indian markets for over a decade and is regarded for consistently identifying early stage investment opportunities. Attorney by qualification, Rajat has done extensive work for improving corporate governance and disclosure standards.

 

Leave a Comment